Imaging Inflammation in Alzheimer's Disease

Alzheimer's Disease Clinical Trial

Official title: Imaging Inflammation in Elders With Different Clinical and Biomarker Profiles of Alzheimer's Disease

Status Enrolling by invitation

Clinical Trial Summary

This study is being done to learn about inflammation and amyloid in Alzheimer's disease. A type of brain scan called a PET scan is used measure 1) inflammation and 2) abnormal accumulation of a the amount of a certain protein fragment called beta-amyloid (plaques) in the brain. These are thought to be involved in Alzheimer's disease. The investigators will also perform brain MRI and do tests to measure the participants' memory and thinking.

Clinical Trial Description

This study is being done to determine the relationship between inflammation, cognitive impairment, and amyloid burden in elderly subjects with different clinical and biomarker profiles of Alzheimer's disease (AD). Participants will undergo amyloid PET imaging with 18F-Florbetaben with target number of completers being 15 amyloid-positive elders with impairment, 15 amyloid-positive elders with normal cognition, 15 amyloid-negative elders with impairment, and 15 amyloid-negative elders with normal cognition. Subjects will undergo screen that includes neuropsychological testing, brain MRI, and PET imaging with 18F-florbetaben to define the above 4 groups. Subjects will have 11C-PBR28 PET imaging to measure the 18 kDa translocator protein (a marker of inflammation). Subjects will have the option to have lumbar puncture performed to measure CSF concentrations of amyloid,tau, phospho-tau, and inflammatory markers. ;

Related Conditions & MeSH terms

• Alzheimer Disease
• Alzheimer's Disease
• Inflammation

• NCT number: NCT02831283
• Study type: Interventional
• Source: Columbia University
• Status: Enrolling by invitation
• Phase: Phase 2
• Start date: June 2016
• Completion date: June 2023